Nomura Adjusts Petronet LNG Outlook Amid West Asia Turmoil
Nomura has maintained a buy rating on Petronet LNG but slashed its target price to Rs 340 from Rs 370, citing potential near-term volume disruptions due to the ongoing crisis in West Asia. Analysts highlighted that the conflict could significantly impact the company's operations, leading to a 23% reduction in its FY27 earnings before interest, taxes, depreciation, and amortisation (EBITDA). This adjustment stems from concerns that the Ras Laffan facility may require several months to resume full operations.
In a recent Reuters interview, Qatar Energy's CEO disclosed that missile strikes have inflicted long-term damage on two of its 14 LNG trains, potentially sidelining 12.8 million tons, or approximately 17% of capacity, for 3-5 years. However, Petronet LNG's management has clarified that India-specific trains remain undamaged, suggesting that supplies to India could recommence once force majeure conditions are lifted.
HSBC Cautions on Blue Star's Valuation
HSBC has assigned a hold rating to Blue Star with a target price of Rs 2,000, describing the company as an expensive standout in the cooling industry. Analysts acknowledged Blue Star's robust research and development capabilities and extensive distribution network, which are poised to bolster market share. The commercial segment helps mitigate seasonal fluctuations, but current valuations are deemed demanding, prompting a cautious stance from HSBC.
BofA Securities Backs HDFC Bank Despite Leadership Change
BofA Securities has issued a buy rating on HDFC Bank, setting a target price at Rs 1,175. Analysts noted that the unexpected departure of the bank's chairman introduces an element of uncertainty, although fundamental strengths remain intact. This exit is believed to reflect personal disagreements with senior management rather than operational issues. HDFC Bank boasts a consistent track record of superior governance over the past 25 years, with no major controversies. Analysts remain constructive, citing attractive valuations and improving operational performance, with sustainable loan growth identified as a key driver for future re-rating.
Citigroup Upgrades Dr Lal Pathlabs to Buy
Citigroup has upgraded Dr Lal Pathlabs from sell to buy, with a target price of Rs 1,650. Analysts observed that India's diagnostics sector has moved beyond COVID-era price wars to more rational competition, as digital platforms have reduced cash burn and predatory pricing has ceased. Despite persistent competition from local standalone and hospital labs, Dr Lal Pathlabs has maintained pricing discipline without broad increases. The company is projected to achieve 10–12% organic revenue growth, fueled by gains in core markets, expansion into Tier 3 and 4 cities, and a richer mix from specialty and Swasthfit offerings. EBITDA margins are expected to stay strong at 28–29%, supported by operating leverage, an improved product mix, cost control, and supply chain efficiencies. A robust, debt-free balance sheet and strong cash flows enable both organic growth and strategic acquisitions. Following a recent correction, valuations appear reasonable, offering an attractive risk-reward profile backed by steady double-digit earnings growth and approximately 25% return on equity.
Motilal Oswal Bullish on Laurus Laboratories
Motilal Oswal Securities has reiterated a buy rating on Laurus Laboratories with a target price of Rs 1,280. Analysts praised the company for deepening relationships with innovator contract development and manufacturing organizations (CDMOs) through capability-led scale-up initiatives. Dedicated capacity build-out is facilitating high-growth adjacencies, and a strategic joint venture with KRKA aims to develop EU and Asia Pacific-focused formulations at scale. Additionally, Laurus Labs is experiencing volume-driven growth in antiretroviral (ARV) segments with stable pricing dynamics, positioning it well for future expansion.
Disclaimer: Recommendations and views on the stock market, other asset classes, or personal finance management tips provided by experts are their own and do not represent the views of The Times of India.
